European Journal of Medical Research - Deutsche AIDS ...

84 EUROPEAN JOURNAL OF MEDICAL RESEARCH
June 27, 2007
load (VL) of 5.00 log10 and a median CD4-T-cell count of
88/l (1-797) at baseline. After a median follow up of 27
months, 96 pts (55 %) had discontinued enfuvirtide, and the
median time on enfuvirtide was 17 months. Main reasons for
discontinuation were virological failure (39 %) and injection
site reactions (21 %).
By ITT-analysis, 25 % and 16 % of the pts had reached a
VL of < 400 and of < 50 copies/ml at week 48, respectively.
Compared to baseline, 47 % had achieved a VL decline of at
least 1 log at week 12. The corresponding CD4-T-cell counts
had increased by 101/l at week 48. By OT-analysis, the percentage
of the pts with a VL < 400 and a VL < 50 copies/ml
were 46 % and 33 % at week 48. Virological response at
month 3 was achieved more frequently in pts with higher CD4
counts (> 100/l) and lower VL at baseline (< 100.000
copies/ml). Reported adherence did not predict virological
outcome.
Conclusions: Enfuvirtide showed a remarkable treatment success
in this large cohort of heavily pretreated patients. Response
rates may be even higher in patients without severe
immunodeficiency or high viremia. Discontinuation rates due
to side effects were relatively low. Efficacy results of this cohort
study are comparable to the 48 week data of the TORO 1
and 2 studies.
D.14 (Poster)
Lopinavir/Ritonavir containing ART during the
pregnancy of HIV-infected women
Sovric M. 1 , Gingelmaier A. 1 , Kästner R. 1 ,
Weissenbacher T. 1 , Mylonas I. 1 , Friese K. 1
1 Ludwig-Maximilians-Universität München, I.
Universitätsfrauenklinik, München, Germany
Objective: Highly active antiretroviral therapy (HAART) is
administered to HIV-infected pregnant women to reduce the
vertical transmission of HIV and/or to provide necessary maternal
treatment due to an advanced disease. The aim of this
study was: a) to evaluate complications during pregnancy and
b) to assess the infant outcome of women taking a
Lopinavir/Ritonavir (LPV/r) containing regimen.
Methods: Retrospective analysis of 38 pregnant women receiving
a LPV/r containing ART at any time of their pregnancy
(years 2002 – 2006). Evaluated parameters: ART, CD4-
count and viral load at the beginning of pregnancy and perinatal,
severe adverse effects of ART, pregnancy complications,
mode of delivery, gestational age (GA) at delivery and infant
outcome.
Results: The 38 pregnancies resulted in 40 live births (92 %
cesarean section, 8% vaginal delivery) and one stillbirth in
GA 33 (complication of the umbilical cord). There were two
cases of successful multiple pregnancies among this cohort
(1x triplets, 1x twins).13 women (35%) had a preterm birth